Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
724.00    0.00 (0.00%)
Bid:
725.00
Ask:
747.00
Spread: 22.00 (3.034%)
Market Cap: £49.23m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Statement re: media speculation

7 Dec 2015 17:36

RNS Number : 2747I
Silver Falcon PLC
07 December 2015
 

7 December 2015

SILVER FALCON PLC

("Silver Falcon" or the "Company")

 

Statement regarding media speculation and share price movement

Silver Falcon PLC (LSE: SILF), the Main Board listed special purpose acquisition company set up to acquire businesses in the FinTech space, notes recent press speculation and movements in its share price.

The Company notes that a number of material pieces of information in recent press speculation are factually incorrect and should not be relied upon.

Whilst the Company has had initial discussions with a possible target concerning a possible transaction, all such discussions are at a preliminary stage. No exclusivity agreement or other binding, or non-binding agreements have been entered into with any party, and there is no certainty that any such agreements will be made. A further announcement will be made in due course.

 

 

For further information please contact:

Camarco Tel: +44 (0) 20 3757 4980

Jennifer Renwick / Billy Clegg / Zoё Moulton

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGGGWPUPAGMM
Date   Source Headline
17th Mar 20257:00 amRNSRecruitment of Second Patient for Clinical Trials
13th Mar 20253:10 pmRNSConversion of convertible loan notes
11th Mar 20257:00 amRNSInstitutional investment
24th Feb 20257:00 amRNSFirst-in-Human Treatment with HG-CT-1
19th Feb 20254:50 pmRNSIssue of convertible loan notes
31st Jan 20259:35 amRNSTotal Voting Rights
8th Jan 20257:00 amRNSPlacing to raise £340,000
2nd Jan 20257:00 amRNSChange of Company Secretary and Registered Office
31st Dec 20247:00 amRNSTotal Voting Rights
30th Dec 20247:00 amRNSOpening of First Clinical Site
19th Dec 20247:00 amRNSUltrafast CAR-T Manufacturing
10th Dec 20244:10 pmRNSAdmission of New Ordinary Shares and New ISIN
9th Dec 20241:30 pmRNSResult of Extraordinary General Meeting
9th Dec 20247:00 amRNSSite Initiation Visit Completed
6th Dec 20247:00 amRNSCBR Macrophage Delivery Update
29th Nov 20247:00 amRNSTotal Voting Rights
22nd Nov 202412:49 pmRNSNotice of Extraordinary General Meeting
22nd Nov 20247:00 amRNSIRB Approval for Phase I Clinical Trial
11th Nov 20247:00 amRNSInstitutional Investment
30th Oct 20247:00 amRNSSchedule for Phase I Clinical Trial Opening
2nd Oct 202411:19 amRNSStrategic Investment from Prevail Partners, LLC
27th Sep 20247:00 amRNSHalf-year Report
9th Sep 20247:00 amRNSFLT3 Assay Ready for Phase I Trials at MD Anderson
2nd Sep 20247:00 amRNSCDX Development Update
28th Aug 20247:00 amRNSPresentation at CBD S&T Conference
27th Jun 20244:39 pmRNSResult of Annual General Meeting
17th Jun 20247:00 amRNSOperations Update
3rd Jun 20247:00 amRNSPosting of Annual Report & Notice of AGM
25th Apr 20247:00 amRNSFinal Results
28th Mar 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSPlacing to Raise US$4.2 million
16th Feb 20247:00 amRNSCBR Brain Delivery
14th Feb 20247:00 amRNSCBR Intranasal Delivery
9th Feb 20247:00 amRNSFDA Consents to Phase I Trials of HEMO-CAR-T
2nd Feb 20247:00 amRNSApproval and Issuance of U.S. Conditioning Patent
16th Jan 20247:00 amRNSSubmission of Complete Response to Clinical Hold
8th Jan 20247:00 amRNSHEMO-CAR-T Process Qualification Run Completed
28th Nov 202312:19 pmRNSPlacing to Raise £534,375
27th Nov 20237:00 amRNSCBR Expanded to Treatment of Cancer
15th Nov 20237:00 amRNSLentivirus Re-manufacturing Completed
31st Oct 20237:00 amRNSTotal Voting Rights
28th Sep 202312:28 pmRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic Investment from Prevail Partners, LLC
14th Sep 20237:00 amRNSClinical Hold Lift Plan is accepted by FDA
8th Sep 20235:11 pmRNSCBR Patent Application Update
10th Jul 20237:00 amRNSFull FDA Review for HEMO-CAR-T IND
30th Jun 20234:07 pmRNSResult of Annual General Meeting
2nd Jun 20232:01 pmRNSPosting of Annual Report & Notice of AGM
2nd Jun 202311:24 amRNSClinical Hold on IND for HEMO-CAR-T
9th May 20237:00 amRNSSubmission of IND for HEMO-CAR-T

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.